🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Proud to share 2-year patient-reported outcomes for our phase II SCIMITAR trial (NCT03541850) of SBRT to the prostate fossa (with or without nodes), out today in JAMA Oncology. jamanetwork.com/journals/jamao…

Our thoughts on Amar Kishan’s latest outstanding clinical trial contribution, this time in biochemically recurrent #pcsm #radonc. Great work, Amar and team. jamanetwork.com/journals/jamao…

We are grateful for the tremendous response to our recent manuscript and want to ensure a precise interpretation of our findings. Our research indicates that local radiation therapy in patients with pre-existing metastases may exert paradoxical effects—reducing the dissemination

I’m heartbroken to learn of President Biden’s diagnosis. President Biden has faced immense challenges throughout his life with resilience and grace. I know he’ll face this battle with the same strength and dignity. My prayers are with him, Dr. Biden, and their entire family

On NPR this morning with Steve Inskeep Tried to give a broader view of metastatic prostate cancer landscape. npr.org/2025/05/19/nx-…

A lot of noise out there. Benjamin J. Davies MD is spot on in this interview. Clear, concise, and correct. Keeping Joe Biden in our family's thoughts. #radonc #pcsm

Great meeting with Rep. Sarah McBride at ASTRO #AdvocacyDay2025. We need your support for #ROCR! Thank you!

Great meeting with Rep. Sarah McBride at ASTRO #AdvocacyDay2025. We need your support for #ROCR!

Thank you to the American Society for Radiation Oncology—and the dedicated oncologists from ChristianaCare—for meeting with me today. We share a simple yet urgent goal: increasing funding for cancer research to save lives.

(1/2) A very exciting milestone for ⁦Volastra Therapeutics⁩ and the field of #Chromosomal_Instability. Early escalation data for our KIF18A inhibitor, VLS-1488, show excellent safety and promising efficacy in heavily pre-treated ovarian cancer patients. businesswire.com/news/home/2025…

This has been a massive undertaking since I started #chualabnccs 7y ago! So pleased to see our work published Cell where we posit a novel model that #TIME delineates progression trajectories of distinct #NPC phenotypes: cell.com/cell-reports-m… Thanks to everyone and

On the eve of #ASCO25, I am delighted to share results from the correlative analyses of the ANZUP phase II TheraP study, now published in Nature Medicine. Massive effort supported by dedicated co-investigators, coordinators, patients & families from 11 study sites across

Remarkable efforts to obtain on-treatment tissue to study TME. CRT with sequential pembro *might* be more favorable than concurrent pembro. ascopubs.org/doi/pdf/10.120… Sana Karam, MD, PhD Nadeem Riaz David Sher Aadel Chaudhuri, MD PhD Scott Bratman

"Thankfully, there are libertarian pubic-interest law firms... ." Yes, and we'll continue to sue any and all administrations whenever they violate the Constitution.

A great question! And one currently being litigated in two federal appeals courts, at least as it applies to inter-state telehealth. Broadly speaking, in the inter-state telehealth setting, specifically w/r/t consultations, we've argued that the requirement that already

🚨 Happening now at #ASCO25: Robin Zon, MD, FACP, FASCO of ASCO introduces Ruth Porat, MBA, MSc, of Alphabet, who is an alum of Memorial Sloan Kettering Cancer Center! ⭐️Stay tuned for more about AI in cancer care from this fantastic guest speaker! #ASCO2025 #ASCOAnnualMeeting

Between cutting Medicaid, slashing medical research, and… whatever… this… is… Republican politicians are really doubling down on their “Let Them Die” agenda.